Abstract Background: The dysregulation of sialylation plays a pivotal role in cancer progression and metastasis, impacting various aspects of tumor behavior. This study aimed to investigate the prognostic significance of long non-coding RNAs (lncRNAs) in relation to sialylation and the functional pathways of Sialic acid-binding immunoglobulin-like lectins (Siglec). Additionally, we aimed to develop a signature of sialylation-related lncRNAs in the context of bladder cancer. Methods: This study used transcriptomic data and clinical information from the TCGA (the Cancer Genome Atlas) database to screen for sialylation-related lncRNAs and constructed a prognostic model. The relationships between these lncRNAs and biological pathways, immune cell infiltration, drug sensitivity, etc., were analyzed, and the expression of some lncRNAs was validated at the cellular level. Results: This study identified 6 prognostic lncRNAs related to sialylation and constructed a risk score model with high predictive accuracy and reliability. The survival period of patients in the high-risk group was significantly lower than that of the low-risk group, and it was related to various biological pathways and immune functions. In addition, this study found differences in the sensitivity of patients in different risk groups to chemotherapy drugs, providing a reference for personalized treatment. Conclusion: This study discovers the prognostic value of a group of sialylation-related lncRNAs in bladder cancer, revealing their association with the tumor microenvironment and treatment response, and providing new molecular markers and potential targets for the diagnosis and treatment of bladder cancer.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: